vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Farmland Partners Inc. (FPI). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $10.7M, roughly 1.9× Arbutus Biopharma Corp). Farmland Partners Inc. runs the higher net margin — 103.4% vs 23.5%, a 79.9% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -3.5%). Over the past eight quarters, Farmland Partners Inc.'s revenue compounded faster (31.4% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
ABUS vs FPI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $20.7M |
| Net Profit | $2.5M | $21.4M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 103.4% |
| Revenue YoY | 522.2% | -3.5% |
| Net Profit YoY | 112.7% | -63.5% |
| EPS (diluted) | $0.01 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.7M | ||
| Q3 25 | — | $11.3M | ||
| Q2 25 | $10.7M | $10.0M | ||
| Q1 25 | — | $10.3M | ||
| Q4 24 | — | $21.5M | ||
| Q3 24 | — | $13.3M | ||
| Q2 24 | — | $11.4M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $483.0K | ||
| Q2 25 | $2.5M | $7.6M | ||
| Q1 25 | — | $2.0M | ||
| Q4 24 | — | $58.7M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | 13.9% | 78.2% | ||
| Q1 25 | — | 20.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 13.9% | ||
| Q2 24 | — | -17.9% | ||
| Q1 24 | — | 11.9% |
| Q4 25 | — | 103.4% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | 23.5% | 76.3% | ||
| Q1 25 | — | 19.9% | ||
| Q4 24 | — | 273.6% | ||
| Q3 24 | — | 13.5% | ||
| Q2 24 | — | -17.5% | ||
| Q1 24 | — | 11.5% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | $0.01 | $0.14 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | — | $1.09 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | $0 | $161.6M |
| Stockholders' EquityBook value | $83.0M | $467.4M |
| Total Assets | $103.3M | $719.1M |
| Debt / EquityLower = less leverage | 0.00× | 0.35× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $161.6M | ||
| Q3 25 | — | $170.4M | ||
| Q2 25 | $0 | $193.4M | ||
| Q1 25 | — | $202.6M | ||
| Q4 24 | — | $204.6M | ||
| Q3 24 | — | $394.0M | ||
| Q2 24 | — | $393.0M | ||
| Q1 24 | — | $383.0M |
| Q4 25 | — | $467.4M | ||
| Q3 25 | — | $457.3M | ||
| Q2 25 | $83.0M | $473.5M | ||
| Q1 25 | — | $492.2M | ||
| Q4 24 | — | $494.6M | ||
| Q3 24 | — | $519.4M | ||
| Q2 24 | — | $521.5M | ||
| Q1 24 | — | $526.7M |
| Q4 25 | — | $719.1M | ||
| Q3 25 | — | $738.5M | ||
| Q2 25 | $103.3M | $776.7M | ||
| Q1 25 | — | $810.5M | ||
| Q4 24 | — | $869.6M | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | 0.00× | 0.41× | ||
| Q1 25 | — | 0.41× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.75× | ||
| Q1 24 | — | 0.73× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $17.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | 0.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.4M | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | $-15.7M | $-2.2M | ||
| Q1 25 | — | $6.4M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $-4.3M | ||
| Q2 24 | — | $-6.1M | ||
| Q1 24 | — | $11.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | -4.04× | ||
| Q2 25 | -6.24× | -0.29× | ||
| Q1 25 | — | 3.12× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | -2.39× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
